Stay updated with breaking news from Aimmune. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
![Aimmune Therapeutics, Inc.: Aimmune Therapeutics to Present New Data for PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp] at the EAACI Hybrid Congress 2022 - Vimarsana News](https://vimarsana.com/images/vimarsana-bigimage.jpg)
Analysis to be Presented Showed Peanut Allergy Treatment with PALFORZIA was Associated with Improvements in Health-Related Quality of Life among Patients and Caregivers -Additional Data to be Presented
Consumer News Jan 11, 2021 11:53 AM By Sabrina Emms A new enzyme treatment is being used to develop hypoallergenic peanuts. Photo courtesy of Shutterstock Harmless to some but anything but to others, a peanut allergy is a big deal. Around 2% of children have allergies to peanuts, which is one of eight recognized major food allergens. In January 2020, pre-Covid, the FDA approved a drug to treat peanut allergies in children. Called Palforzia, it isn’t a traditional drug, but instead a "peanut allergen powder" made of peanut powder and peanut protein. Palforzia conditions the i...